KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Moderna (MRNA) EBITDA Margin (2017 - 2025)

Moderna (MRNA) has disclosed EBITDA Margin for 9 consecutive years, with 126.4% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin rose 258.0% to 126.4% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 158.13% through Dec 2025, down 3372.0% year-over-year, with the annual reading at 158.13% for FY2025, 3622.0% down from the prior year.
  • EBITDA Margin for Q4 2025 was 126.4% at Moderna, down from 25.59% in the prior quarter.
  • The five-year high for EBITDA Margin was 75.02% in Q4 2021, with the low at 972.22% in Q1 2025.
  • Average EBITDA Margin over 5 years is 181.55%, with a median of 11.71% recorded in 2024.
  • The sharpest move saw EBITDA Margin soared 170286bps in 2021, then tumbled -73843bps in 2024.
  • Over 5 years, EBITDA Margin stood at 75.02% in 2021, then crashed by -59bps to 31.08% in 2022, then crashed by -99bps to 0.21% in 2023, then tumbled by -60530bps to 128.99% in 2024, then increased by 2bps to 126.4% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 126.4%, 25.59%, and 638.73% for Q4 2025, Q3 2025, and Q2 2025 respectively.